NEWRON PHARMA N/ IT0004147952 /
| 12/11/2024 17:31:37 | Chg. -0.410 | Volume | Bid18:09:20 | Ask18:09:20 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 7.380CHF | -5.26% | 69,033 Turnover: 520,043.290 |
7.260Bid Size: 2,500 | 7.800Ask Size: 459 | 131.7 mill.CHF | - | - |
Assets
|
2010 IFRS in mill. EUR |
2011 IFRS in mill. EUR |
2012 IFRS in mill. EUR |
2013 IFRS in mill. EUR |
2014 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | .1000 | .1000 | .1000 | .1000 | .1000 | ||||||
| Intangible Assets | 5.2000 | 5.2000 | 11.2000 | 9.1000 | 7 | ||||||
| Long-Term Investments | .6000 | .6000 | .6000 | .6000 | .6000 | ||||||
| Fixed Assets | 6 | 5.9000 | 11.9000 | 9.8000 | 7.7000 | ||||||
| Inventories | .4000 | .2000 | .2000 | .3000 | .1000 | ||||||
| Accounts Receivable | - | - | - | - | - | ||||||
| Cash and Cash Equivalents | 8.1000 | 5.4000 | 29.2000 | 18.4000 | 18.8000 | ||||||
| Current Assets | 13.1000 | 7.6000 | 32.7000 | 21.8000 | 29.4000 | ||||||
| Total Assets | 19.1000 | 13.6000 | 44.7000 | 31.6000 | 37.1000 | ||||||
Liabilities
|
2010 IFRS in mill. EUR |
2011 IFRS in mill. EUR |
2012 IFRS in mill. EUR |
2013 IFRS in mill. EUR |
2014 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 4.2000 | 2.4000 | 6.3000 | 3.7000 | 3.8000 | ||||||
| Long-term debt | - | 1.8000 | 1.4000 | 1.1000 | .7000 | ||||||
| Liabilities to Banks | 0.0000 | 2.2000 | 1.8000 | 1.5000 | 1.1000 | ||||||
| Provisions | 1.7000 | 1.7000 | 3.5000 | 2.9000 | 2.3000 | ||||||
| Liabilities | 6.9000 | 7 | 17 | 10.5000 | 7.8000 | ||||||
| Share Capital | 1.5000 | 1.5000 | 2.3000 | 2.3000 | 2.6000 | ||||||
| Total Equity | 12.2000 | 6.6000 | 27.6000 | 21.1000 | 29.3000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 19.1000 | 13.6000 | 44.7000 | 31.6000 | 37.1000 | ||||||
Income Statement
|
2010 IFRS in mill. EUR |
2011 IFRS in mill. EUR |
2012 IFRS in mill. EUR |
2013 IFRS in mill. EUR |
2014 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | .8000 | 4.3000 | 8.9000 | 3.5000 | 1.6000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -21.6000 | -6.5000 | -2.7000 | -7.8000 | -11.2000 | ||||||
| Interest Income | - | - | - | - | - | ||||||
| Income Before Taxes | -21.7000 | -6.4000 | -2.5000 | -7.7000 | -10.7000 | ||||||
| Income Taxes | 1.2000 | 0.0000 | .1000 | .6000 | .6000 | ||||||
| Minority Interests Profit | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Net Income | -20.5000 | -6.4000 | -2.4000 | -7.1000 | -10.1000 | ||||||
Per Share
Cash Flow
|
2010 IFRS in mill. EUR |
2011 IFRS in mill. EUR |
2012 IFRS in mill. EUR |
2013 IFRS in mill. EUR |
2014 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -19.1000 | -4.9000 | 5.8000 | -10.7000 | -10 | ||||||
| Cash Flow from Investing Activities | 1.6000 | .1000 | 10 | .2000 | -6.9000 | ||||||
| Cash Flow from Financing | 2.9000 | 2.2000 | 8 | -.4000 | 17.2000 | ||||||
| Decrease / Increase in Cash | -14.6000 | -2.7000 | 23.9000 | -10.8000 | .3000 | ||||||
| Employees | 39 | 31 | 23 | 23 | 23 | ||||||
